Andrew Seidman, MD
Memorial Sloan Kettering Cancer Center
6
6
4
N/A
0
18
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+1 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (6)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
min yan
Henan Cancer Hospital
Shared therapeutic areas:
Dong-Xin Wang, MD, PhD
Peking University First Hospital
Shared therapeutic areas:
XiaoFeng Shen, MD
Nanjing Medical University
Shared therapeutic areas:
Puma
Biotechnology
Shared therapeutic areas:
Michael B Gill
Power Life Sciences Inc.
Shared therapeutic areas:
David S Schrump, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Norman Wolmark, MD
NSABP Foundation Inc
Shared therapeutic areas:
Worked with same sponsors:
Lizhi Niu, PhD
Fuda Cancer Hospital
Shared therapeutic areas:
Brigitte C Widemann, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Ali MA Ismail, lecturer
Cairo University
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (6)
Showing 6 of 6 trials
A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain
Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM)
18F-FLT-PET Imaging of the Brain in Patients With Metastatic Breast Cancer to the Brain Treated With Whole Brain Radiation Therapy With or Without Sorafenib: Comparison With MR Imaging of the Brain
Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer
Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer
Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases
All 6 trials loaded